Abstract Number: 2745 • 2019 ACR/ARP Annual Meeting
Iguratimod Treated Scleroderma with Interrupted Egr1/TGF-β Loop
Background/Purpose: Iguratimod is a novel disease modifying anti-rheumatic drug that has been approved for treating rheumatoid arthritis in East Asia. Transcription factor early growth response…Abstract Number: 2746 • 2019 ACR/ARP Annual Meeting
Dimethyl Fumarate Ameliorates the GATA6 Deficiency-Induced Pulmonary Hypertension by Normalizing Oxidative and ER Stress
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with limited form of systemic sclerosis (SSc). We have previously reported that…Abstract Number: 2747 • 2019 ACR/ARP Annual Meeting
Identification of Naturally Presented Peptides of the Autoantigen Topoisomerase-I Reveals a Common Pathogenic Mechanism in Patients with Systemic Sclerosis
Background/Purpose: Autoimmune responses to DNA topoisomerase-I (TOP1) are found in a subset of patients with scleroderma at high risk for interstitial lung disease (ILD) and…Abstract Number: 2748 • 2019 ACR/ARP Annual Meeting
Cracking a Novel Profibrotic Molecular Mechanism: lncRNA H19X and DDIT4L Crosstalk
Background/Purpose: Long noncoding RNAs (lncRNAs) are an emerging class of noncoding transcripts involved in the regulation of gene expression in health and disease. LncRNAs function…Abstract Number: 2749 • 2019 ACR/ARP Annual Meeting
Long Non-coding RNA HOTAIR Induces Myofibroblast Activation in Systemic Sclerosis Through EZH2 Dependent De-repression of NOTCH Signalling Pathway Activation
Background/Purpose: Fibroblasts explanted from affected tissues in Systemic Sclerosis (SSc), conserve their pro-fibrotic phenotype characterised by increased secretion of collagens and other extracellular matrix proteins…Abstract Number: 2750 • 2019 ACR/ARP Annual Meeting
Development and Preliminary Validation of a Novel Lung Ultrasound Interpretation Criteria for the Detection of Interstitial Lung Disease in Patients with Systemic Sclerosis
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc), and screening, characterization, and monitoring of disease activity are important for therapeutic…Abstract Number: 2751 • 2019 ACR/ARP Annual Meeting
Very Low Prevalence of Ultrasound Determined Tendon Abnormalities in Healthy Subjects Throughout the Age Range: An Outcome Measures in Rheumatology (OMERACT) Ultrasound Minimal Disease Study
Background/Purpose: Tenosynovitis (TS) is a common, often clinically undetectable finding in Rheumatoid Arthritis (RA). Recent data showed TS on ultrasound (US) has a role in…Abstract Number: 2752 • 2019 ACR/ARP Annual Meeting
Successfull Evaluation of a Predefined Set of Anatomic Sites in the Pelvis of Patients with Polymyalgia Rheumatica Showing Extracapsular Inflammation as Visualized by Contrast Enhanced Magnetic Resonance Imaging
Background/Purpose: The diagnosis of polymyalgia rheumatica (PMR) is based on a thorough clinical evaluation of the patient - including exclusion of other diseases, since there…Abstract Number: 2753 • 2019 ACR/ARP Annual Meeting
Major Salivary Gland Ultrasound: Pilot Study of Findings and Feasibility in Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Background/Purpose: Ultrasonography is becoming an increasingly useful tool in evaluating patients in pediatric rheumatology. It is predominantly used for musculoskeletal assessments, however, major salivary gland…Abstract Number: 2754 • 2019 ACR/ARP Annual Meeting
AxSpA Patients with Symptom Onset < 30 Years Have More Structural Lesions on MRI of the Sacroiliac Joints When Fulfilling the Modified New York Criteria
Background/Purpose: The modified New York criteria (mNY) combine clinical symptoms with radiographic sacroiliitis on conventional pelvic radiographs (X-SI) classifying radiographic axial SpA patients (r-axSpA). AxSpA…Abstract Number: 2755 • 2019 ACR/ARP Annual Meeting
Assessing the Sensitivity to Change of the OMERACT Ultrasound Structural Gout Lesions During Urate-Lowering Therapy
Background/Purpose: To evaluate the sensitivity to change of ultrasound (US) structural gout lesions, as defined by the OMERACT US group, in gout patients during urate…Abstract Number: 2756 • 2019 ACR/ARP Annual Meeting
Subcutaneous Tanezumab versus NSAID for the Treatment of Osteoarthritis: Joint Safety Events in a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
Background/Purpose: Tanezumab, a monoclonal antibody inhibiting nerve growth factor (NGF), is under investigation for the treatment of chronic pain conditions. In prior osteoarthritis (OA) studies,…Abstract Number: 2757 • 2019 ACR/ARP Annual Meeting
Clinical Effectiveness of Ultrasound-guided Intra-articular Corticosteroid and Local Anaesthetic Injections for Hip Osteoarthritis: A Randomised Controlled Trial (HIT)
Background/Purpose: Evidence of the effectiveness of intra-articular corticosteroid injection for hip osteoarthritis (OA) is limited and conflicting. The HIT trial compared the clinical effectiveness of…Abstract Number: 2758 • 2019 ACR/ARP Annual Meeting
Nortriptyline in Knee Arthritis (Nortika): A Randomised Controlled Double Blind Trial of Nortriptyline for Pain in Knee Osteoarthritis
Background/Purpose: Osteoarthritis (OA) is the most common joint disease and is a major cause of pain and disability There is currently no cure for OA…Abstract Number: 2759 • 2019 ACR/ARP Annual Meeting
Stopping NSAIDs for Arthritis Pain (SNAP): A Randomized Withdrawal Trial Comparing NSAIDs to Cognitive Behavioral Therapy
Background/Purpose: NSAIDs are associated with uncertain long-term benefits and significant toxicity in patients with knee osteoarthritis (OA). Our objective was to evaluate if discontinuing NSAIDs…
ACR Meeting Abstracts